Ductal carcinoma in situ of the breast: Impact of pathology on therapeutic decisions

American Journal of Surgical Pathology

Volumn 27, Issue 6, 2003, Pages 828-831

  Jensen, Roy A ^a,b   Page, David L ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast; Ductal carcinoma in situ

Indexed keywords

BREAST BIOPSY; BREAST CARCINOMA; CALCIFICATION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CARCINOMA IN SITU; CELL STRUCTURE; CONFERENCE PAPER; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; MAMMOGRAPHY; MEDICAL DECISION MAKING; NECROSIS; RECURRENCE RISK;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MASTECTOMY; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); RADIOTHERAPY;

EID: 0038515310     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200306000-00015     Document Type: Conference Paper

References (27)

1. Bellamy COC, McDonald C, Salter DM, et al. Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 1993;24:16-23.
2. Betsill WL Jr, Rosen PP, Lieberman PH, et al. Intraductal carcinoma: long-term follow-up after treatment by biopsy alone. JAMA 1978;239:1863-7.
3. Bijker N, Peterse JL, Duchateau L, et al. Histological type and marker expression of the primary tumor compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2001;84:539-44.
4. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001;19:2263-71.
5. Bijker N, Rutgers EJ, Duchateau L, et al. Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients. Cancer 2001;91:472-7.
6. Chan KC, Knox WF, Sinha G, et al. Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ. Cancer 2001;91:9-16.
7. Chaudary MA, Millis R, Lane EB. Paget's disease of the nipple: a ten year review including clinical, pathologic, and immunohistochemical findings. Breast Cancer Res Treat 1986;8:139-46.
8. Dean L, Geschickter CF. Comedo carcinoma of the breast. Arch Surg 1939;36:225.
9. Fechner R. One century of mammary carcinoma in situ: what have we learned. Am J Clin Pathol 1994;100:654-61.
10. Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer [Abstract]. N Engl J Med 1993;328:1581-6.
11. Holland R, Hendriks JHCL, Verbeek ALM, et al. Extent, distribution, and mammographic/histologic correlations of breast ductal carcinoma in situ. Lancet 1990;335:519-22.
12. Lagios MD, Margolin FR, Westdahl PR, et al. Mammographically detected duct carcinoma in situ: frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989;63:618-24.
13. Lennington WJ, Jensen RA, Dalton LW, et al. Ductal carcinoma in situ of the breast: heterogeneity of individual lesions. Cancer 1994;73:118-24.
14. Ottesen GL, Graversen HP, Blichert-Toft M, et al. Ductal carcinoma in situ of the female breast: short-term results of a prospective nationwide study. Am J Surg Pathol 1992;16:1183-96.
15. Page DL, Dupont WD, Rogers LW, et al. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995;76:1197-200.
16. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 1992;23:1095-7.
17. Patchefsky AS, Schwartz GF, Finkelstein SD, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989;63:731-41.
18. Pierce SM, Schnitt S, Harris A. What to do about mammographically detected ductal carcinoma in situ? Cancer 1992;70:2576-8.
19. Schnitt SJ, Connolly JL, Tavassoli FA, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 1996;16:1133-43.
20. Schwartz GF. Finkel GC, Garcia JC, et al. Subclinical ductal carcinoma in situ of the breast: treatment by excision and surveillance alone. Cancer 1992;70:2468-74.
21. Schwartz GF, Lagios MD, et al. Consensus conference on the classification of ductal carcinoma in situ. Cancer 1997;80:1798802.
22. Scott MA, Lagios MD, Axelsson K, Schnitt SJ, et al. Ductal carcinoma in situ of the breast: reproducibility of histologic subtype analysis. Hum Pathol 1997:28:967-73.
23. Silverstein MJ, Lagios MD, Craig PH. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996;77:2267-74.
24. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999;340:1455-61.
25. Silverstein MJ, Waisman J, Gamagami P. et al. Intraductal carcinoma of the breast (208 cases): clinical factors influencing treatment choice. Cancer 1990;66:102-8.
26. Solin LJ, Yeh I-T, Kurtz J, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Cancer 1993;71:2532-42.
27. van Dongen JA, Holland R, Peterse JL, et al. Ductal carcinoma in situ of the breast: second EORTC consensus meeting [Abstract]. Eur J Cancer 1992;28:626-9.